Palvella Therapeutics PVLA
NASDAQ PVLA
$132.73 -5.20 (-3.77%)
At close: Oct 1, 2026 · 4:00 PM EDT

Palvella Therapeutics (PVLA) Preferred Stock Liabilities (2022 - 2023)

Updated

Palvella Therapeutics' Preferred Stock Liabilities came in at $70.6 million for Q4 2023, unchanged from $70.6 million a year earlier.

Analysis

Palvella Therapeutics (PVLA) Preferred Stock Liabilities (2022 - 2023) Analysis & Trends

  • Going back by year, Preferred Stock Liabilities was $70.6 million in FY2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -
10 Palvella Therapeutics 1.99 Bn 1.73 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 70.60 Mn
Dec 31, 2022 70.60 Mn
API Access

Palvella Therapeutics Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=PVLA&period=max&api_key=YOUR_API_KEY